Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth ... year to $13.5 billion from $9.3 billion. Earnings per share came in at $4.99, underperforming Wall ...
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs ... who was attending boot camp five days a week, was at her thinnest — 160 pounds.
People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why
open image in gallery A small percentage of patients taking weight loss and diabetes drugs like Ozempic and Zepbound have experienced ... and Wegovy, as per the approved labels.
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled ... pharmaceutical news highlights from this week. An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn ...
Zepbound, another weight-loss drug, was taken off the compounding ... The reaction: Last week, Senators Richard Durbin, a Democrat, and Roger Marshall, a Republican, criticized Hims & Hers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback